Short answer
Guardant Health, Inc. (GH) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $302M (up 48.3% year over year) with net income of −$112M.
Q1 2026 key financials · XBRL
- Revenue
- $302M
- +48.3% YoY
- Net income
- −$112M
- −17.8% YoY
- Operating margin
- -40.2%
- EPS (diluted)
- −$0.85
- −10.4% YoY
Source: XBRL data from the Guardant Health, Inc. (GH) Q1 2026 10-Q on SEC EDGAR. USD.
Guardant Health, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $301.7M, up 48% YoY from $203.5M
- Screening best performer: $41.6M, up 633% YoY; oncology $205.0M, up 36%
- Operating margin -40.2% vs -54.6% YoY; net loss $112.1M vs $95.2M
- Cash, restricted cash and marketable securities approximately $1.2B at March 31, 2026
- Near-term headwinds: reimbursement variability, coding changes, rising research and development spending
Risk Factors
- No material risk-factor changes during Q1 fiscal 2026 versus the December 31, 2025 10-K
- Healthcare-industry and company-specific risks remain capable of materially harming operations, cash flows, and stock price
- Historical financial performance remains unreliable for forecasting future results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Guardant Health, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.